RE:NewsThis is a good news for me. The main concern for a company like PLI is to be able to fund the R&D until they can bring to the market their drugs. Hematech was agood deal at the time, but dealing in early stage cost 50% of the future revenues. If PBI-4050 reach the market, the more the piece of the pie will be, the more the company will value. Just don't forget that Intermune was bough for over 8 billions for the IPF drug only. So, even if there's a billion shares outstanding, and if PBI-4050 made only in IPF, that's still $8.00/share of future value. And I'm not talking yet about other 4050 applications, nor orphan drugs and proteins extraction made with the PPPS. So, I can live with a small dilution.....